Atopic Dermatitis Clinical Trials

54 studies are recruiting for atopic dermatitis in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

   Background: Autosomal dominant hyper-IgE syndrome (HIES), also called Job syndrome, is a genetic disorder that affects the immune system. It can cause skin and lung infections and problems with blood vessels, connective tissues, and bones. People with HIES often have lupus-like disease or atopic de…

   Stage

   Phase 1

   Ages

   12 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT07262983 on ClinicalTrials.gov

2. Studies of Skin Microbes in Healthy People and in People With Skin Conditions

   This study will examine microbes (e.g., bacteria, fungi, viruses) that live on human skin and how microbes contribute to health and disease. It will analyze healthy human skin and how the these microorganisms might change in patients with atopic dermatitis (AD), a skin condition also known as eczem…

   Stage

   Not phased

   Ages

   2 to 100

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Human Genome Research Institute (NHGRI)

   See if you can join NCT00605878 on ClinicalTrials.gov

3. Natural History and Genetics of Food Allergy and Related Conditions

   Background: - About 15 million Americans have a food allergy. Because there are no cures or effective prevention or treatment for food allergies, researchers want to learn more about them. Objective: - To learn more about the causes and effects of food allergy and related conditions. Eligibility: *…

   Stage

   Not phased

   Ages

   0 to 99

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT02504853 on ClinicalTrials.gov

4. Metabolic Profiling of Immune Responses in Immune-mediated Diseases

   Background: The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal. Researchers want to learn more to better treat conditions that affect immu…

   Stage

   Not phased

   Ages

   18 to 75

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT04864886 on ClinicalTrials.gov

5. Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

   This study will collect skin measurements from people with atopic dermatitis (AD) using the investigational Nevisense Go device. Participants aged 12 to 89 years with a history of AD flares will use the device at home for about 90 days. Participants will complete device measurements, electronic dia…

   Stage

   Not phased

   Ages

   12 to 89

   Site

   U.S. Dermatology Partners, Phoenix, Arizona

   Locations

   10 in total

   Run by

   Castle Biosciences Incorporated

   See if you can join NCT07645820 on ClinicalTrials.gov

6. A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

   The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Atd002 52001, Troy, Michigan

   Locations

   68 in total

   Run by

   UCB Biopharma SRL

   See if you can join NCT07277660 on ClinicalTrials.gov

7. The Impact of Dietary Salt on the Severity of Eczema

   The goal of this clinical trial is to evaluate the feasibility of low-sodium diet to improve eczema severity. The main questions it aims to answer are: * Does a low-sodium diet improve eczema severity? * How does a low-sodium diet impact skin sodium concentration? * Is skin sodium concentration ass…

   Stage

   Phase 4

   Ages

   18 and older

   Site

   San Francisco VA Medical Center, San Francisco, California

   Locations

   2 in total

   Run by

   University of California, San Francisco

   See if you can join NCT07447063 on ClinicalTrials.gov

8. A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

   This is a multicenter, double-blind, Long-Term Extension (LTE) study to evaluate the long-term safety and efficacy of APG777 in patients with moderate-to-severe AD who have completed treatment in an APG777 Parent Study (NCT06395948). The LTE study will consist of 3 periods: 1) Screening Visit will …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Investigational Site, Fountain Valley, California

   Locations

   71 in total

   Run by

   Apogee Therapeutics, Inc.

   See if you can join NCT07003425 on ClinicalTrials.gov

9. Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis

   Atopic dermatitis is well reported to have a significant impact on well-being in adolescents with atopic dermatitis, without clear recommendations for intervention. The investigators aim to identify an accessible, effective digital health intervention for these patients. The investigators hypothesi…

   Stage

   Not phased

   Ages

   13 to 17

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   2 in total

   Run by

   Weill Medical College of Cornell University

   See if you can join NCT07746427 on ClinicalTrials.gov

10. A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

    This 24-month study will assess the long-term safety and efficacy of liquid abrocitinib oral suspension with or without topical medications in children 2 years of age or older with moderate-to-severe atopic dermatitis. The study will enroll two groups: participants who have completed other abrociti…

    Stage

    Phase 3

    Ages

    2 to 11

    Site

    Cahaba Dermatology & Skin Health Center, Birmingham, Alabama

    Locations

    41 in total

    Run by

    Pfizer

    See if you can join NCT06807281 on ClinicalTrials.gov

11. A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

    The purpose of this study is to learn if the study medicine (PF-08049820) is safe and effective for the treatment of atopic dermatitis (AD), also known as eczema, or atopic eczema. People with this condition may have severe itching and rashes on the skin. The study is seeking participants who: 1. A…

    Stage

    Phase 2

    Ages

    18 to 64

    Site

    Marvel Clinical Research, Huntington Beach, California

    Locations

    23 in total

    Run by

    Pfizer

    See if you can join NCT07216027 on ClinicalTrials.gov

12. A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

    This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UCLA Division of Dermatology, Los Angeles, California

    Locations

    29 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT07223697 on ClinicalTrials.gov

13. A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

    This is a Phase 2, two-stage, adaptive, 1:1 randomized, double-blind, vehicle-controlled clinical study evaluating the efficacy, safety, and tolerability of GX-03 topical ointment in adult subjects with atopic dermatitis (eczema). Stage 1 (Completed): Stage 1 comprised an initial cohort of 50 subje…

    Stage

    Phase 2

    Ages

    18 to 80

    Site

    ALS Global, Irving, Texas

    Run by

    Turn Therapeutics

    See if you can join NCT07355075 on ClinicalTrials.gov

14. A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema

    The purpose of this study is to find out how well tilrekimig works, how safe it is, and how it affects the body when used together with medicated creams or ointments in adults and adolescents with moderate to severe atopic dermatitis (eczema). Eczema (also called atopic dermatitis) is a common skin…

    Stage

    Phase 3

    Ages

    12 and older

    Site

    GCP Research , Global Clinical Professionals, St. Petersburg, Florida

    Locations

    3 in total

    Run by

    Pfizer

    See if you can join NCT07765888 on ClinicalTrials.gov

15. A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

    This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.

    Stage

    Phase 2

    Ages

    18 to 65

    Site

    AllerVie Clinical Research, Birmingham, Alabama

    Locations

    85 in total

    Run by

    Apollo Therapeutics Ltd

    See if you can join NCT07599813 on ClinicalTrials.gov

16. CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness

    This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for patients with atopic dermatitis under the care of a licensed dermatologist or qualified physician extender. Secondary objectives include analyz…

    Stage

    Not phased

    Ages

    18 and older

    Site

    CorEvitas, LLC, Waltham, Massachusetts

    Run by

    CorEvitas

    See if you can join NCT04504955 on ClinicalTrials.gov

17. Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis

    This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

    Stage

    Phase 2

    Ages

    18 to 100

    Site

    Novartis Investigative Site, Birmingham, Alabama

    Locations

    105 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06947993 on ClinicalTrials.gov

18. Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

    This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the…

    Stage

    Not phased

    Ages

    12 and older

    Site

    Allergy and Asthma Medical Group and Research Center, San Diego, California

    Run by

    Pfizer

    See if you can join NCT06899204 on ClinicalTrials.gov

19. Cardamom and Topical Roseomonas in Atopic Dermatitis

    Background: Atopic dermatitis (AD), also called eczema, is a chronic skin condition. AD can make skin dry and itchy, and sometimes it can lead to serious health problems, such as asthma, food allergies, eye infections, and sleep problems. No cure exists for AD. Researchers know that people with AD …

    Stage

    Phase 2

    Ages

    2 to 100

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Allergy and Infectious Diseases (NIAID)

    See if you can join NCT06096857 on ClinicalTrials.gov

20. A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)

    This is a Phase 1, randomized, blinded, placebo controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

    Stage

    Phase 1

    Ages

    18 to 72

    Site

    First OC Dermatology, Irvine, California

    Locations

    14 in total

    Run by

    Bambusa Therapeutics

    See if you can join NCT06808477 on ClinicalTrials.gov

21. Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.

    This study is being done to obtain descriptive classifications of pruritus using a patient directed survey system and assess change in pruritus over time in patients with Atopic Dermatitis over 4 weeks with use of topical Roflumilast cream 0.15% QD.

    Stage

    Phase 4

    Ages

    12 and older

    Site

    Integrative Skin Science and Research, Sacramento, California

    Run by

    Integrative Skin Science and Research

    See if you can join NCT07560618 on ClinicalTrials.gov

22. A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

    The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

    Stage

    Phase 2

    Ages

    18 to 74

    Site

    Inmagene Site 1, Lancaster, California

    Locations

    30 in total

    Run by

    Inmagene LLC

    See if you can join NCT07037901 on ClinicalTrials.gov

23. A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

    Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Topical therapies applied over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study compares upadacitinib to dupil…

    Stage

    Phase 3

    Ages

    2 to 11

    Site

    Applied Research Center and Wellness Clinic /ID# 268547, Little Rock, Arkansas

    Locations

    150 in total

    Run by

    AbbVie

    See if you can join NCT06461897 on ClinicalTrials.gov

24. This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

    The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. …

    Stage

    Not phased

    Ages

    12 and older

    Site

    Cahaba Dermatology & Skin Health Center- Site Number : 8400006, Birmingham, Alabama

    Locations

    79 in total

    Run by

    Sanofi

    See if you can join NCT07290803 on ClinicalTrials.gov

25. A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

    This double-blind, placebo-controlled study is designed to evaluate the safety and efficacy of ENV-294 in adults with moderate-to-severe atopic dermatitis (AD). The study will compare three dose levels of ENV-294 with placebo administered for 12 weeks. Participants will undergo screening, receive s…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Enveda Investigative Site, Encinitas, California

    Locations

    9 in total

    Run by

    Enveda Therapeutics

    See if you can join NCT07643766 on ClinicalTrials.gov